Centro Oncológico Korben
En el Centro Oncológico Korben contamos con un destacado equipo de médicos y coordinadores altamente capacitados, comprometidos con la investigación y el tratamiento del cáncer, encabezados por el Director Médico Ernesto Korbenfeld.Select an option
I am a doctor
I am a sponsor
Specializations
Cáncer de mama, pulmón, vejiga y próstata.
Our team
Medical staff
El Dr. Ernesto Korbenfeld es médico oncólogo, especialista en Medicina Interna y Oncología Clínica. Egresado de la UBA, cuenta con certificación de la ESMO. Realizó un fellowship en el Hospital Británico y una Maestría en Oncología Molecular (UBA y Fundación Leloir). Completó un máster en Madrid sobre Bases Moleculares del Cáncer. Fue distinguido por la Legislatura porteña como personalidad destacada en salud.
Investigador principal y director médicoErnesto Korbenfeld
Médico Oncólogo Clínico - Subinvestigador en protocolos de mamaFernando Petracci
Médica Oncóloga Clínica - Subinvestigadora en protocolos de pulmónMaría Victoria Faura
Médica Oncóloga Clínica - Subinvestigadora en protocolos de mama y vejigaDaiana Gandolfi
Médico Oncólogo Clínico - Investigador principal y subinvestigador en protocolos de pulmónNicolás Minatta
Médica Oncóloga Clínica - Subinvestigadora en protocolos de pulmónAlejandra Scocimarro
Open studies
Breast Cancer
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer - EMBER-4 - Eli Lilly and CompanySee more
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer - INAVO122 - Hoffmann-La RocheSee more
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) - CAMBRIA-2 - AstraZenecaSee more
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) - PionERA - Hoffmann-La RocheSee more
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer - INAVO123 - Hoffmann-La RocheSee more
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence - ELEGANT - Stemline Therapeutics, Inc.See more
Lung cancer
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) - CodeBreaK 202 - AmgenSee more
A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004) - MK-1084-004 - Merck Sharp & Dohme LLCSee more
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer - Krascendo 1 - Hoffmann-La RocheSee more
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) - GlaxoSmithKlineSee more
Head and neck cancer
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone - Boehringer IngelheimSee more
Urothelial cancer
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 - KEYNOTE-D78 - Seagen Inc.See more
